Quick Answer
LianBio reported Operating Income of -$125.35 million for fiscal year 2022.
LianBio Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2022 | -$125.35M | +35.9% |
| 2021 | -$195.57M | -45.0% |
| 2020 | -$134.87M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2023 | -$26.30M | -7.1% | -5.0% |
| June 30, 2023 | -$25.04M | +41.9% | +3.6% |
| March 31, 2023 | -$25.97M | +8.6% | -5.8% |
| September 30, 2022 | -$24.55M | -81.3% | +43.1% |
| June 30, 2022 | -$43.14M | +56.6% | -51.8% |
| March 31, 2022 | -$28.42M | +53.0% | -109.8% |
| September 30, 2021 | -$13.54M | — | +86.4% |
| June 30, 2021 | -$99.49M | — | -64.5% |
- LianBio showed an increase of +35.9% in Operating Income compared to the prior fiscal year.
- Over the 2020–2022 period, LianBio’s operating income has grown by 7.1% (from -$134.87 million to -$125.35 million).
- The most recent figure is from LianBio’s fiscal year 2022 report (Form 10-K), filed with the SEC on March 28, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: